• Acridine Orange hydrochloride: Technical Guide for Nucleic A

  2026-07-08

  Acridine Orange hydrochloride (SKU B7747) enables rapid, dual-color discrimination of DNA and RNA in cytochemical workflows, addressing common bottlenecks in apoptosis detection, cell cycle analysis, and flow cytofluorometric nucleic acid staining. This product is optimized for in situ fluorescence applications but is not recommended for long-term solution storage or protocols requiring persistent reagent stability.

• BAPTA-AM: Practical Guidelines for Intracellular Calcium Che

  2026-07-08

  BAPTA-AM enables researchers to precisely regulate intracellular calcium concentrations, supporting studies of calcium signaling, apoptosis, and neuroprotection. It is best deployed in controlled in vitro settings where selective chelation of Ca²⁺ is required and magnesium interference is managed. Use in systems where calcium-mimicking or magnesium sensitivity is critical should be carefully controlled.

• 17-AAG (Tanespimycin): Precision HSP90 Inhibition for Pathwa

  2026-07-07

  Explore how 17-AAG (Tanespimycin) enables high-fidelity HSP90 chaperone inhibition and deep mechanistic insight in cancer research. This article uniquely bridges molecular mechanisms, emerging findings on regulated cell death, and advanced assay strategy.

• Spatially Localized BDNF Release Directs Early NMJ Postsynap

  2026-07-07

  This study uncovers a mechanism by which muscle-derived BDNF, trafficked to podosome-like structures, is locally and activity-dependently released to regulate initial acetylcholine receptor clustering at neuromuscular junctions. The findings clarify how spatial and proteolytic control of BDNF—requiring precise vesicular targeting and MMP/furin-mediated processing—coordinates postsynaptic apparatus formation, offering new avenues for dissecting synaptic development and its modulation.

• HDAC Inhibition Reverses EBV-Induced Dedifferentiation in NP

  2026-07-06

  The reference study uncovers how HDAC inhibitors can reverse Epstein-Barr virus (EBV)-induced dedifferentiation in nasopharyngeal carcinoma (NPC) by restoring CEBPA expression, providing a mechanistic basis for differentiation therapy in solid tumors. These findings highlight the role of epigenetic regulation in tumor plasticity and suggest new avenues for targeted cancer therapy.

• CDK9 Inhibitor (A3294): Protocol Guidance and Workflow Setup

  2026-07-06

  CDK9 inhibitor (A3294) enables precise, selective inhibition of cyclin dependent kinase 9 for research into transcription elongation and HIV-1 propagation, minimizing off-target and cytotoxic effects. It is not suitable for broad-spectrum CDK inhibition or protocols requiring long-term storage of working solutions.

• Dextran Sulfate Sodium Salt (MW 35000-45000) in IBD Models

  2026-07-05

  Dextran sulfate sodium salt (MW 35000-45000) is the gold-standard tool for reproducibly modeling intestinal inflammation and epithelial repair in mouse models of inflammatory bowel disease. This guide delivers optimized protocols, troubleshooting strategies, and practical insights bridging the latest GPR35-KLF5 research with translational ulcerative colitis workflows.

• Bergenin Targets γδT17 Cells in Psoriasis via PPARγ–PROX1 Ax

  2026-07-04

  This study demonstrates that bergenin, derived from Bergenia purpurascens, ameliorates psoriasis by selectively targeting pathogenic γδT17 cells through a novel PPARγ–mediated ubiquitination and degradation of PROX1. The findings provide a mechanistic basis for exploiting plant-derived PPARγ agonists in immune-mediated skin diseases and open new avenues for cell-type-specific intervention.

• Gap26 Connexin 43 Mimetic Peptide: Unlocking Intercellular S

  2026-07-03

  Gap26 offers precise, reversible control over gap junction-mediated communication, empowering researchers to dissect calcium signaling, ATP release, and mitochondrial transfer in advanced cellular and animal models. This article demystifies protocol design, troubleshooting, and translational use-cases that make Gap26 indispensable for vascular, neurobiological, and inflammation research.

• Geneticin, G-418 Sulfate: Mechanisms, Glutamine Metabolism,

  2026-07-03

  Explore how G418 Sulfate (Geneticin) reshapes genetic engineering and antiviral research, with a scientific deep-dive into its ribosomal inhibition pathway and an innovative perspective on glutamine metabolism's role in cell line development.

• Targeting Glutamine Metabolism in HSCs Reduces Liver Fibrosi

  2026-07-02

  The referenced study demonstrates that inhibiting glutamine metabolism in hepatic stellate cells (HSCs), particularly by modulating SIRT4 and glutamate dehydrogenase (GDH) activity, leads to significant attenuation of liver fibrosis. These findings provide a mechanistic basis for antifibrotic therapies targeting metabolic pathways, offering new avenues for translational research in chronic liver disease.

• AMPK-JAK2/STAT3 Axis in M1 Macrophage Polarization and Obesi

  2026-07-02

  This study reveals that AMPK downregulation drives M1 macrophage polarization and airway inflammation in obesity-related asthma, while AMPK activation attenuates these effects via the JAK2/STAT3 pathway. The findings highlight AMPK as a mechanistic link and potential therapeutic target for asthma phenotypes associated with metabolic dysfunction.

• Carbapenemase Gene Dynamics in Enterobacter cloacae: New Ins

  2026-07-01

  This study provides a detailed molecular and epidemiological characterization of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae from Guangdong, China. By analyzing the distribution, transmissibility, and resistance profiles of these genes, the research advances our understanding of multidrug resistance mechanisms and highlights urgent surveillance needs.

• Evaluating Cefoperazone's Antibacterial Activity Versus New

  2026-07-01

  This article analyzes a landmark comparative study of N-formimidoyl thienamycin (MK0787) and several advanced β-lactam antibiotics—including cefoperazone—against multidrug-resistant clinical isolates. The study’s rigorous methodology and findings inform nuanced assay design and antibiotic selection for research targeting gram-negative resistance and β-lactamase stability.

• Applied Protocols with CHIR-99021: Stem Cell Differentiation

  2026-06-30

  CHIR-99021 (CT99021) delivers exceptional selectivity for GSK-3 inhibition, empowering researchers to fine-tune pluripotency, lineage commitment, and vasculogenesis in advanced stem cell platforms. This guide details optimized workflows, troubleshooting tips, and applied insights—bridging foundational research and practical execution.

16558 records 1/1104 page Next 12345 下5页 Last page